Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

J.K. Litton; S.A. Hurvitz; L.A. Mina; H.S. Rugo; K.-H. Lee; A. Gonçalves; S. Diab; N. Woodward; A. Goodwin; R. Yerushalmi

doi:10.1016/j.annonc.2020.08.2098

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Identifier:nobleid.org/w1/20260526/220C75CF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/220C75CF.svg?ark=w1%2F20260526%2F220C75CF)](https://nobleid.org/work/w1/20260526/220C75CF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Identifier:nobleid.org/w1/20260526/220C75CF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/220C75CF.svg?ark=w1%2F20260526%2F220C75CF)](https://nobleid.org/work/w1/20260526/220C75CF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work